-

Gilead Sciences Contributes Additional $85 Million to Its Foundation to Advance Health Equity

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company's vision of creating a healthier world for all people. This donation builds on the endowment Gilead announced last year to recapitalize the Gilead Foundation, with a new vision and mission to create impact in the community and society by encouraging a culture of giving, engaging in local communities and exploring innovative approaches to complex social issues.

“Our additional contribution to the Gilead Foundation demonstrates our continued commitment to supporting communities and advancing health equity,” said Andrew Dickinson, Chief Financial Officer, Gilead Sciences and Director, Gilead Foundation. “We are proud to dedicate our philanthropic resources in this way because we believe a more just society is a healthier one.”

One of the Gilead Foundation’s giving pillars is the innovative Creating Possible Fund, which will announce its inaugural cohort of grants later this fall with the theme of Advancing Health Prosperity Through Education Equity, which is focused on addressing systemic barriers to equitable education for underserved and excluded adolescents. Research is clear that closing gaps in educational outcomes is necessary to promote health equity for underserved and excluded communities. The Gilead Foundation is committed to supporting efforts to ensure that all people have full and equal access to educational and economic opportunities that enable them to lead healthy lives.

The Gilead Foundation also supports charitable programs in local communities where Gilead employees live and work. Near its headquarters in San Mateo County, the Gilead Foundation recently provided the local school district with funding for STEM programming, as well as support for a mobile education and health program for underserved farmworker communities.

“Gilead is a pioneer in corporate stewardship and investing in the local community,” said Annie Tsai, Board President, San Mateo-Foster City Education Foundation. “It has been an honor to collaborate with the Gilead Foundation on expanding opportunities for STEM learning at SMFCSD, San Mateo County's largest public school district. As we live in an area with one of the largest wealth gaps in the country, achieving educational equity for all of our community's children is our priority and we are thrilled that Gilead has chosen to invest their resources into this important initiative.”

The Gilead Foundation also encourages a culture of employee giving through its donation matching program for employees, Giving Together.

“We have seen how generous our employees are – a recent matching donation program for employees in support of humanitarian relief efforts in Ukraine has raised more than $750,000 to date, in addition to the $3 million donated by the Gilead Foundation,” said Jyoti Mehra, Executive Vice President, Human Resources, Gilead Sciences and Director, Gilead Foundation. “Gilead’s employees work hard to bring new possibilities to millions of patients around the world, and they are equally committed to creating new possibilities for health prosperity for all people through the Gilead Foundation.”

The Gilead Foundation is one example of the philanthropic reach of the company, whose global corporate giving is recognized as the number one funder in HIV: https://www.gilead.com/news-and-press/press-room/press-releases/2022/5/gilead-reaches-number-one-spot-as-top-overall-philanthropic-funder-of-hivrelated-programs-according-to-funders-concerned-about-aids-report.

For more information on the Gilead Foundation, visit: https://www.gilead.com/purpose/giving/gilead-foundation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead’s medicines today reach millions of people in low- and middle-income countries around the world.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, CFA, Investors
(650) 358-1054

Hayley Home, Media
(916) 402-2864

Gilead Sciences, Inc.

NASDAQ:GILD

Release Versions

Contacts

Jacquie Ross, CFA, Investors
(650) 358-1054

Hayley Home, Media
(916) 402-2864

More News From Gilead Sciences, Inc.

Gilead Sciences to Release Fourth Quarter & Full Year 2025 Financial Results on Tuesday, February 10, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2025 financial results and guidance will be released on Tuesday, February 10, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2025 financial results and provide a business update. A live webcast will be available in the Investors section of www.gilead.com an...

New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer (TNBC). ASCENT-04 successfully met its primary endpoint of progression-free survival (PFS) with a 35% (HR: 0.65;...

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference on Monday, January 12, 2026 beginning at 11:15 a.m. Pacific Time The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and...
Back to Newsroom